Securities code: 002589 securities abbreviation: Realcan Pharmaceutical Group Co.Ltd(002589) Announcement No.: 2022-006 Realcan Pharmaceutical Group Co.Ltd(002589)
Announcement on the resolutions of the 18th meeting of the 4th board of directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements and major omissions.
The notice of the 18th meeting of the Fourth Board of directors of Realcan Pharmaceutical Group Co.Ltd(002589) (hereinafter referred to as “the company” and ” Realcan Pharmaceutical Group Co.Ltd(002589) “) was sent in writing on January 17, 2022 and held in the conference room on the fourth floor of the company, 326 Airport Road, Yantai City on the morning of January 21, 2022 by on-site and communication voting. The meeting was presided over by the chairman, Mr. Han Xu. There were 9 directors who should attend the meeting, 9 actually attended the meeting, and the company’s supervisors attended the meeting as nonvoting delegates. The meeting was held in accordance with the company law of the people’s Republic of China and other laws and regulations and the articles of association. After effective voting, the meeting formed the following resolutions:
1、 Deliberated and adopted the proposal on the renewal of accounting firm
The board of directors intends to renew the appointment of tianyuanquan Certified Public Accountants (special general partnership) as the company’s auditor in 2021 for one year. The audit fee is proposed to be submitted to the general meeting of shareholders to authorize the company’s management to negotiate and determine with the audit institution in accordance with the market fair and reasonable pricing principle.
The proposal was adopted by 9 votes in favor, 0 against and 0 abstention.
The specific contents of this proposal are detailed in the announcement on the renewal of the appointment of accounting firms. The independent directors of the company have issued prior approval opinions and relevant independent opinions on the proposal. For the specific contents, see China Securities News, securities times, Shanghai Securities News, securities daily and cninfo（ http://www.cn.info.com.cn. ）Disclosure of.
This proposal needs to be submitted to the first extraordinary general meeting of shareholders of the company in 2022 for deliberation.
2、 The proposal on using idle self owned funds to purchase financial products was deliberated and adopted
In order to make rational use of idle self owned funds and increase the company’s income, the company plans to apply for a self owned fund limit of 1 billion yuan for the purchase of financial products. Within the above limit, the funds can be recycled and used. Meanwhile, the management of the company is authorized to exercise the investment decision-making power, and the person in charge of Finance and the person in charge of capital department are responsible for the specific purchase. The authorization period shall be valid for two years from the effective date.
The proposal was adopted by 9 votes in favor, 0 against and 0 abstention.
For details of this proposal, please refer to the announcement on purchasing financial products with idle self owned funds. The independent directors of the company have issued relevant independent opinions on this proposal. For details, please refer to China Securities News, securities times, Shanghai Securities News, securities daily and cninfo.com（ http://www.cn.info.com.cn. ）Disclosure of.
3、 The proposal on convening the first extraordinary general meeting of shareholders in 2022 was deliberated and adopted
The company plans to hold the first extraordinary general meeting of shareholders in 2022 at 15:00 p.m. on February 9, 2022 in the company’s conference room. For details, see China Securities News, securities times, Shanghai Securities News, securities daily and cninfo（ http://www.cn.info.com.cn. ）Notice on convening the first extraordinary general meeting of shareholders in 2022.
The proposal was adopted by 9 votes in favor, 0 against and 0 abstention
It is hereby announced.
Documents for future reference:
Resolutions of the board of directors signed by the attending directors.
Other documents required by SZSE.
Realcan Pharmaceutical Group Co.Ltd(002589) board of directors
January 24, 2022
